These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 12651912)
1. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. Long IS; Han K; Li M; Shirasawa S; Sasazuki T; Johnston M; Tsao MS Mol Cancer Res; 2003 Mar; 1(5):393-401. PubMed ID: 12651912 [TBL] [Abstract][Full Text] [Related]
2. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer. Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056 [TBL] [Abstract][Full Text] [Related]
3. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398 [TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma. Price JA; Kovach SJ; Johnson T; Koniaris LG; Cahill PA; Sitzmann JV; McKillop IH Hepatology; 2002 Nov; 36(5):1089-97. PubMed ID: 12395318 [TBL] [Abstract][Full Text] [Related]
5. High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells. To C; Seiden I; Liu N; Wigle D; Tsao MS Exp Cell Res; 2002 Feb; 273(1):45-53. PubMed ID: 11795945 [TBL] [Abstract][Full Text] [Related]
6. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene. Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607 [TBL] [Abstract][Full Text] [Related]
7. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062 [TBL] [Abstract][Full Text] [Related]
8. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation. Nakamura T; Kanda S; Yamamoto K; Kohno T; Maeda K; Matsuyama T; Kanetake H Oncogene; 2001 Nov; 20(52):7610-23. PubMed ID: 11753639 [TBL] [Abstract][Full Text] [Related]
9. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. Firon M; Shaharabany M; Altstock RT; Horev J; Abramovici A; Resau JH; Vande Woude GF; Tsarfaty I Oncogene; 2000 May; 19(20):2386-97. PubMed ID: 10828880 [TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Bergström JD; Westermark B; Heldin NE Exp Cell Res; 2000 Aug; 259(1):293-9. PubMed ID: 10942601 [TBL] [Abstract][Full Text] [Related]
11. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Matsushita A; Götze T; Korc M Cancer Res; 2007 Nov; 67(21):10309-16. PubMed ID: 17974973 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy. Stabile LP; Lyker JS; Huang L; Siegfried JM Gene Ther; 2004 Feb; 11(3):325-35. PubMed ID: 14737093 [TBL] [Abstract][Full Text] [Related]
13. Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity. Liang H; O'Reilly S; Liu Y; Abounader R; Laterra J; Maher VM; McCormick JJ Int J Oncol; 2004 May; 24(5):1057-67. PubMed ID: 15067326 [TBL] [Abstract][Full Text] [Related]
14. Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. Qiao H; Hung W; Tremblay E; Wojcik J; Gui J; Ho J; Klassen J; Campling B; Elliott B J Cell Biochem; 2002; 86(4):665-77. PubMed ID: 12210733 [TBL] [Abstract][Full Text] [Related]
15. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Herynk MH; Stoeltzing O; Reinmuth N; Parikh NU; Abounader R; Laterra J; Radinsky R; Ellis LM; Gallick GE Cancer Res; 2003 Jun; 63(11):2990-6. PubMed ID: 12782608 [TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Hecht M; Papoutsi M; Tran HD; Wilting J; Schweigerer L Cancer Res; 2004 Sep; 64(17):6109-18. PubMed ID: 15342394 [TBL] [Abstract][Full Text] [Related]
17. Characterization of p21Ras-mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines. Liou JS; Chen JS; Faller DV J Cell Physiol; 2004 Feb; 198(2):277-94. PubMed ID: 14603530 [TBL] [Abstract][Full Text] [Related]
18. GD₃ synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Cazet A; Lefebvre J; Adriaenssens E; Julien S; Bobowski M; Grigoriadis A; Tutt A; Tulasne D; Le Bourhis X; Delannoy P Mol Cancer Res; 2010 Nov; 8(11):1526-35. PubMed ID: 20889649 [TBL] [Abstract][Full Text] [Related]
19. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991 [TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1. Recio JA; Merlino G Cancer Res; 2003 Apr; 63(7):1576-82. PubMed ID: 12670907 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]